Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical CoTAK -1.39%76 Equity-to-Asset is 0.48 as of Jun. 2026, which is 2% above its 10-year median of 0.47. GuruFocus rates TAK with a GF Score™ of 76/100 and a GF Value™ of $14.45 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks worse than 67.23% on this metric.
Takeda Pharmaceutical Co (NYSE:TAK) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Takeda Pharmaceutical Co Equity-to-Asset Related Terms
Takeda Pharmaceutical Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's Equity-to-Asset falls into.
Takeda Pharmaceutical Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Takeda Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (TAK) has a Equity-to-Asset of 0.48 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Takeda Pharmaceutical Co and its competitors. This is near median its historical median of 0.47. Over the past decade, Takeda Pharmaceutical Co's Equity-to-Asset has ranged from 0.35 to 0.51. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #677 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 67.2%.
Is Takeda Pharmaceutical Co's Equity-to-Asset too high?
Takeda Pharmaceutical Co's current Equity-to-Asset of 0.48 is near median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.51. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Takeda Pharmaceutical Co's value of 0.48 is 20% below this industry median. Based on the distribution chart, Takeda Pharmaceutical Co ranks #677 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #677 out of 1007 companies for Equity-to-Asset. This places Takeda Pharmaceutical Co in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Takeda Pharmaceutical Co's value of 0.48 is 20% below this benchmark. Historically, Takeda Pharmaceutical Co's own Equity-to-Asset has ranged from 0.35 to 0.51 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.60, Takeda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takeda Pharmaceutical Co's current Equity-to-Asset of 0.48 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Takeda Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current Equity-to-Asset is 0.48, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.45, compared to a current price of $18.45 — trading 27.7% above its estimated fair value. The current Equity-to-Asset is 0.48, which is near median its 10-year median of 0.47 and 20% below the Drug Manufacturers industry median of 0.60. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Equity-to-Asset is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $18.45 is trading 27.7% above its estimated GF Value™ of $14.45.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TAK:
Equity-to-Asset: 0.48 (near median its 10-year median of 0.47)
GF Value™: $14.45 vs. price of $18.45 (27.7% above fair value)
Industry Position: 20% below the Drug Manufacturers median (#677 of 1007)
No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score
Get the complete analysis for TAK
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TAK has been successfully added to your 
